Cortisone and the "Pill"


One research program led by Djerassi focused on the conversion of diosgenin to cortisone. Early in 1949, Philip Hench and Edward Kendall at the Mayo Clinic had reported spectacular results from the treatment of rheumatoid arthritis with cortisone. Newspapers featured stories of crippled arthritics dancing in the streets after therapy. The medical community soon recognized the value of cortisone (and cortisol) in the treatment of other inflammatory conditions, but it was too expensive for widespread use. At that time, cortisone could only be made by a laborious 36-step Merck & Co. process that started with desoxycholic acid isolated from ox bile. Syntex completed its synthesis of cortisone from diosgenin; however, this achievement immediately was overtaken by another scientific breakthrough.

In 1951, scientists at the Upjohn Co. introduced a microbiological process, which specifically oxidized progesterone to a product that was easily converted to cortisone. As Rosenkranz later recalled, " . . . in July 1951, I received a phone call from Upjohn asking me whether we would be able to accept an order for 10 tons of progesterone at 48 cents per gram. The going price at the time was in the $2 range and the quantity was unheard of." Soon, most cortisone was manufactured by Upjohn's process using Syntex progesterone, although the Merck route was improved enough to remain competitive.

Syntex also competed with other drug companies in the hunt for an effective oral contraceptive. Because progesterone prevents ovulation during pregnancy, research focused on the discovery of an orally active progesterone mimic. Using expertise obtained in the conversion of testosterone to estradiol and estrone, along with two important leads from the chemical literature, Djerassi's group designed and, in 1951, synthesized norethindrone, the active ingredient in the first practical oral contraceptive. For many reasons, the first "pill" to be marketed was G. D. Searle and Co.'s norethynodrel, but norethindrone accounted for more than half of the oral contraceptive market in the 1970s.

By the 1950s, Syntex and its competitors in Mexico* were producing more than half the sex hormones sold in the United States. Syntex's economic success was matched by its scientific reputation, which was boosted by a very liberal publication policy. Contributions made by Syntex accounted for more than 30% of all industrial citations in the Fiesers' definitive 1959 monograph, Steroids. In 1951, Fortune magazine headlined: "Syntex makes the biggest technological boom ever heard south of the border." Considering the impact the Mexican steroid industry would have on world health and culture, Fortune greatly underestimated the power of the explosion.


* Besides Diosynth and others, these competitors included Glidden and, later, Laboratories Julian, the independent institute of Percy L. Julian (link), Glidden's former research director. Julian's starting material was stigmasterol, a steroid isolated from soybean oil.


 

next | back | home

 

The Decade of the Sex Hormones | To Orizaba and beyond | A steroid industry in Mexico | Syntex prospers | Cortisone and the "Pill" | The life of Russell Marker | Landmark designation

Copyright ©2004 American Chemical Society. All Rights Reserved. 1155 16th Street NW, Washington DC 20036
202-872-4600, 800-227-5558